Fluid Resuscitation and Progression to Renal Replacement Therapy in Patients With COVID-19

被引:3
|
作者
Holt, Daniel B. [1 ]
Lardaro, Thomas [1 ]
Wang, Alfred Z. [1 ]
Musey, Paul I., Jr. [1 ]
Trigonis, Russell [1 ]
Bucca, Antonino [1 ]
Croft, Alexander [1 ]
Glober, Nancy [1 ]
Peterson, Kelli [1 ]
Schaffer, Jason T. [1 ]
Hunter, Benton R. [1 ]
机构
[1] Indiana Univ Sch Med, Dept Med, Div Pulm & Crit Care, Indianapolis, IN 46202 USA
来源
JOURNAL OF EMERGENCY MEDICINE | 2022年 / 62卷 / 02期
关键词
acute kidney injury; coronavirus; COVID-19; hemodialysis; renal replacement therapy; resuscitation; MANAGEMENT; SEPSIS;
D O I
10.1016/j.jemermed.2021.10.026
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Coronavirus disease 2019 (COVID-19) is associated with respiratory symptoms and renal effects. Data regarding fluid resuscitation and kidney injury in COVID-19 are lacking, and understanding this relationship is critical. Objectives: To determine if there is an association between fluid volume administered in 24 h and development of renal failure in COVID-19 patients. Methods: Retrospective chart review; 14 hospitals in Indiana. Included patients were adults admitted between March 11, 2020 and April 13, 2020 with a positive test for severe acute respiratory syndrome coronavirus 2 within 3 days of admission. Patients requiring renal replacement therapy prior to admission were excluded. Volumes and types of resuscitative intravenous fluids in the first 24 h were obtained with demographics, medical history, and other objective data. The primary outcome was initiation of renal replacement therapy. Logistic regression modeling was utilized in creating multivariate models for determining factors associated with the primary outcome. Results: The fluid volume received in the first 24 h after hospital admission was associated with initiation of renal replacement therapy in two different multivariate logistic regression models. An odds ratio of 1.42 (95% confidence interval 1.01-1.99) was observed when adjusting for age, heart failure, obesity, creatinine, bicarbonate, and total fluid volume. An odds ratio of 1.45 (95% confidence interval 1.02-2.05) was observed when variables significant in univariate analysis were adjusted for. Conclusions: Each liter of intravenous fluid administered to patients with COVID-19 in the first 24 h of presentation was independently associated with an increased risk for initiation of renal replacement therapy, supporting judicious fluid administration in patients with this disease. (C) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:145 / 153
页数:9
相关论文
共 50 条
  • [1] CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) IN COVID-19 PATIENTS
    Castaneda, Jorge
    Kovvuru, Karthik
    [J]. CRITICAL CARE MEDICINE, 2021, 49 (01) : 145 - 145
  • [2] COVID-19 Computed tomography patterns in renal replacement therapy patients
    do Carmo, Gabriel Assis Lopes
    Oliveira, Mariana Paiva
    Campos, Anna Luiza Lino
    Couto, Braulio Roberto Goncalves Marinho
    do Carmo, Lilian Pires de Freitas
    Cerqueira, Tiago Lemos
    Souza, Camila Alencar Monteiro de
    Goll, Yan Lopes
    de Souza, Vitor Santos
    Vieira, Mariana Oliveira Guimaraes
    de Castro, Pedro Alves Soares Vaz
    Lemos, Pedro Augusto Botelho
    Simoes e Silva, Ana Cristina
    [J]. JORNAL BRASILEIRO DE NEFROLOGIA, 2024, 46 (03):
  • [3] Anticoagulation in COVID-19 patients requiring continuous renal replacement therapy
    Attallah, Nizar
    Gupta, Sudeendra
    Madhyastha, Rakesh
    El Nekidy, Wasim S.
    Mallat, Jihad
    [J]. ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2021, 40 (03)
  • [4] ANTICOAGULATION AND THROMBOEMBOLISM IN COVID-19 PATIENTS ON CONTINUOUS RENAL REPLACEMENT THERAPY
    Lawson, Shannon
    Rabinovich, Marina
    Curry, Marjorie
    [J]. CRITICAL CARE MEDICINE, 2021, 49 (01) : 115 - 115
  • [5] COVID-19 in patients receiving renal replacement therapy in the Russian Federation
    Shilov, E. M.
    Rumiantseva, E. I.
    Shilova, M. M.
    Milchakov, K. S.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2021, 31
  • [6] Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy
    Frittoli, Michela
    Cassia, Matthias
    Barassi, Alessandra
    Ciceri, Paola
    Galassi, Andrea
    Conte, Ferruccio
    Cozzolino, Mario Gennaro
    [J]. VACCINES, 2022, 10 (09)
  • [7] COVID-19 Diagnosis by Computed Tomography in Renal Replacement Therapy Patients
    Carmo, Lilian
    Cerqueira, Tiago L.
    Lemos, Pedro Augusto B.
    Vieira, Mariana O.
    Oliveira, Mariana D.
    Couto, Braulio R.
    Souza, Camila A.
    Goll, Yan L.
    de Souza, Vitor S.
    Soares Vaz de Castro, Pedro Alves
    Simoes e Silva, Ana Cristina
    Carmo, Gabriel A.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 893 - 893
  • [8] Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy
    Roberts, Lara N.
    Bramham, Kate
    Sharpe, Claire C.
    Arya, Roopen
    [J]. KIDNEY INTERNATIONAL REPORTS, 2020, 5 (09): : 1377 - 1380
  • [9] Kinetics of SuPAR hemoadsorption in critical COVID-19 patients on renal replacement therapy
    Vaidas Vicka
    Elija Januskeviciute
    Ieva Bartuševiciene
    Donata Ringaitiene
    Aiste Aleknaviciene
    Mindaugas Serpytis
    Laurynas Rimsevicius
    Marius Miglinas
    Ligita Jancoriene
    Jurate Sipylaite
    [J]. BMC Nephrology, 23
  • [10] Interpreting serum procalcitonin in COVID-19 patients undergoing renal replacement therapy
    Adams, Briony
    Beaney, Alec
    [J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 27 : 324 - 325